Mirae Asset Global Investments Co., Ltd. Intellia Therapeutics, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

$24 Billion
Q4 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,394 shares of NTLA stock, worth $41,304. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,394

Previous 3,674 7.62%

Holding current value

$41,304

Previous $75,000 48.0%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 27, 2025	SELL	$11.41 - $21.09 $3,194 - $5,905	-280 Reduced 7.62%	3,394 $39,000
Q3 2024 Oct 23, 2024	BUY	$19.72 - $27.36 $15,657 - $21,723	794 Added 27.57%	3,674 $75,000
Q2 2024 Jul 30, 2024	SELL	$20.02 - $27.22 $4.29 Million - $5.84 Million	-214,514 Reduced 98.68%	2,880 $64,000
Q1 2024 May 01, 2024	BUY	$23.82 - $32.8 $751,187 - $1.03 Million	31,536 Added 16.97%	217,394 $5.98 Million
Q4 2023 Jan 24, 2024	SELL	$23.16 - $32.34 $2.34 Million - $3.26 Million	-100,885 Reduced 35.18%	185,858 $5.67 Million
Q3 2023 Oct 26, 2023	BUY	$31.62 - $45.78 $715,655 - $1.04 Million	22,633 Added 8.57%	286,743 $9.07 Million
Q2 2023 Aug 10, 2023	BUY	$34.58 - $46.03 $1.6 Million - $2.13 Million	46,381 Added 21.3%	264,110 $10.8 Million
Q1 2023 May 04, 2023	BUY	$33.3 - $44.82 $314,951 - $423,907	9,458 Added 4.54%	217,729 $8.11 Million
Q4 2022 Feb 09, 2023	SELL	$33.21 - $62.69 $104,677 - $197,598	-3,152 Reduced 1.49%	208,271 $7.27 Million
Q3 2022 Nov 10, 2022	BUY	$53.92 - $71.7 $1.72 Million - $2.29 Million	31,898 Added 17.77%	211,423 $11.8 Million
Q2 2022 Jul 26, 2022	BUY	$38.49 - $76.21 $3.99 Million - $7.9 Million	103,651 Added 136.61%	179,525 $9.29 Million
Q1 2022 May 10, 2022	SELL	$58.27 - $118.99 $798,706 - $1.63 Million	-13,707 Reduced 15.3%	75,874 $5.51 Million
Q4 2021 Feb 08, 2022	SELL	$100.76 - $138.36 $4.98 Million - $6.84 Million	-49,434 Reduced 35.56%	89,581 $10.6 Million
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $3.46 Million - $4.62 Million	26,113 Added 23.13%	139,015 $18.6 Million
Q2 2021 Aug 11, 2021	BUY	$60.88 - $161.91 $97,651 - $259,703	1,604 Added 1.44%	112,902 $18.3 Million
Q1 2021 May 13, 2021	BUY	$46.59 - $83.68 $2.35 Million - $4.23 Million	50,496 Added 83.05%	111,298 $8.93 Million
Q4 2020 Feb 10, 2021	BUY	$18.83 - $63.53 $446,270 - $1.51 Million	23,700 Added 63.88%	60,802 $3.31 Million
Q3 2020 Nov 12, 2020	BUY	$17.47 - $24.93 $206,058 - $294,049	11,795 Added 46.61%	37,102 $738,000
Q2 2020 Aug 11, 2020	BUY	$11.14 - $22.87 $107,512 - $220,718	9,651 Added 61.64%	25,307 $532,000
Q1 2020 May 12, 2020	BUY	$9.44 - $15.58 $16,066 - $26,517	1,702 Added 12.2%	15,656 $191,000
Q4 2019 Feb 12, 2020	BUY	$10.43 - $17.67 $35,535 - $60,201	3,407 Added 32.3%	13,954 $205,000
Q3 2019 Nov 12, 2019	BUY	$13.07 - $18.51 $137,849 - $195,224	10,547 New	10,547 $141,000

Others Institutions Holding NTLA

# of Institutions

336

Shares Held

96.1M

Call Options Held

1.06M

Put Options Held

863K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $925M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Intellia Therapeutics, Inc. Transaction History